Thorsten P. Degenhardt
Direttore operativo presso Mycovia Pharmaceuticals, Inc.
Profilo
Thorsten P.
Degenhardt is currently the Chief Operating Officer at Mycovia Pharmaceuticals, Inc. He previously worked as a Project Director at BioStratum, Inc. and as a Vice President-Drug Development at Cempra Pharmaceuticals, Inc. Prior to his industry experience, he was an Assistant Professor at the University of South Carolina.
Degenhardt holds a graduate degree from Technische Universität Darmstadt and a doctorate from Ruprecht-Karls-Universität Heidelberg.
Posizioni attive di Thorsten P. Degenhardt
| Società | Posizione | Inizio |
|---|---|---|
Mycovia Pharmaceuticals, Inc.
 Mycovia Pharmaceuticals, Inc. BiotechnologyHealth Technology Mycovia Pharmaceuticals, Inc. develops novel drugs in areas of unmet medical need, with an initial focus in women?s health. Its product candidate, VT-1161, engages in developed as a treatment for recurrent vulvovaginal candidiasis. The company was founded in 2018 and is headquartered in Durham, NC. | Direttore operativo | - |
Precedenti posizioni note di Thorsten P. Degenhardt
| Società | Posizione | Fine |
|---|---|---|
BioStratum, Inc.
 BioStratum, Inc. Pharmaceuticals: MajorHealth Technology BioStratum, Inc. develops and distributes pharmaceutical products. Its products are used for treatment of diabetes and diabetic complications. The firm also develops anti-tumor, cancer, diabetic kidney disease and diabetic eye disease drugs. The company was founded by Karl Tryggvason and J. Wesley Fox in 1994 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
| University of South Carolina | Corporate Officer/Principal | - |
Cempra Pharmaceuticals, Inc.
 Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | - |
Formazione di Thorsten P. Degenhardt
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| Technische Universität Darmstadt | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Cempra Pharmaceuticals, Inc.
Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Health Technology |
BioStratum, Inc.
BioStratum, Inc. Pharmaceuticals: MajorHealth Technology BioStratum, Inc. develops and distributes pharmaceutical products. Its products are used for treatment of diabetes and diabetic complications. The firm also develops anti-tumor, cancer, diabetic kidney disease and diabetic eye disease drugs. The company was founded by Karl Tryggvason and J. Wesley Fox in 1994 and is headquartered in Durham, NC. | Health Technology |
Mycovia Pharmaceuticals, Inc.
Mycovia Pharmaceuticals, Inc. BiotechnologyHealth Technology Mycovia Pharmaceuticals, Inc. develops novel drugs in areas of unmet medical need, with an initial focus in women?s health. Its product candidate, VT-1161, engages in developed as a treatment for recurrent vulvovaginal candidiasis. The company was founded in 2018 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Thorsten P. Degenhardt
